{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:02:49Z","timestamp":1784908969452,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bone and joint infections (BJI) require prolonged antibiotic therapy that may amplify cumulative toxicity risk, yet indication-contextualized safety data remain sparse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the FDA Adverse Event Reporting System (FAERS, 2004Q1-2025Q4; 20,006,981 deduplicated cases), we identified 9,072 cases involving 17 BJI-target antibiotics. Four disproportionality measures, namely reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayes geometric mean (EBGM), were applied against the full FAERS database. We then performed BJI within-cohort contextualization, primary-suspect-only (PS-only) sensitivity analysis, exploratory XGBoost machine learning, and Weibull time-to-onset (TTO) modeling, in accordance with the READUS-PV reporting framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 153 drug-adverse drug event (ADE) pairs, 103 met the prespecified four-method robust full-FAERS signal criterion; 28 were retained after BJI within-cohort contextualization. Indication-supported signals included vancomycin-nephrotoxicity (within-cohort ROR 3.30, 95% CI 2.95\u20133.70), linezolid-hematologic toxicity (3.65, 3.21\u20134.16), ceftaroline-hematologic toxicity (4.81, 3.42\u20136.77), and ertapenem-neurotoxicity (4.76, 3.50\u20136.47). Several strong full-FAERS signals (e.g., fluoroquinolone-tendon and broad-spectrum-C. difficile infection) were attenuated within the BJI cohort or under PS-only restriction, highlighting the role of prescribing pattern and reporting-role confounding. Weibull modeling indicated predominantly early-onset reporting patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Multi-method, indication-contextualized FAERS analysis distinguishes BJI-supported from general reporting signals and provides a transparent framework for prioritizing monitoring during prolonged antibiotic therapy. Findings are hypothesis-generating and require validation in controlled observational studies. They prioritize safety signals rather than providing estimates of incidence, absolute risk, causality, dose-response, or renal-function effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1887555","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:12:16Z","timestamp":1784905936000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibiotic-associated adverse events in bone and joint infections: a FAERS pharmacovigilance study"],"prefix":"10.3389","volume":"13","author":[{"given":"Haoping","family":"Dai","sequence":"first","affiliation":[{"name":"Department of Spine Surgery, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Spine Surgery, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Spine Surgery, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMra040181","article-title":"Prosthetic-joint infections","volume":"351","author":"Zimmerli","year":"2004","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the IDSA","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","article-title":"Osteomyelitis","volume":"364","author":"Lew","year":"2004","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938","article-title":"Association of adverse events with antibiotic use in hospitalized patients","volume":"177","author":"Tamma","year":"2017","journal-title":"JAMA Intern Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"B6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijantimicag.2010.02.019","article-title":"Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction","volume":"36","author":"Matsumoto","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"B7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40264-013-0089-8","article-title":"Tendon injury and fluoroquinolone use: a systematic review","volume":"36","author":"Stephenson","year":"2013","journal-title":"Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat."},{"key":"B13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","article-title":"Novel data-mining methodologies for adverse drug event discovery and analysis","volume":"91","author":"Harpaz","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1145\/2939672.2939785","article-title":"\u201cXGBoost: a scalable tree boosting system,\u201d in Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining","author":"Chen","year":"2016"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.5555\/3295222.3295230","article-title":"A unified approach to interpreting model predictions","volume":"30","author":"Lundberg","year":"2017","journal-title":"Adv Neural Inf Process Syst."},{"key":"B18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"B19","unstructured":"FDA Adverse Event Monitoring System (AEMS) Quarterly Data Extract Files, formerly FAERS\n          \n          2026"},{"key":"B20","volume-title":"Medical Dictionary for Regulatory Activities (MedDRA) Introductory Guide, Version 27.0.","author":"International","year":"2024"},{"key":"B21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the Weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/jac\/dkt129","article-title":"Community-associated Clostridium difficile infection and antibiotics: a meta-analysis","volume":"68","author":"Deshpande","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"B25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.anaerobe.2016.06.008","article-title":"Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Pr\u00e9vot 1938","volume":"40","author":"Lawson","year":"2016","journal-title":"Anaerobe."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/jac\/dkw062","article-title":"High incidence of neutropenia in patients with prolonged ceftaroline exposure","volume":"71","author":"Furtek","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"B27","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/phar.2301","article-title":"Comparison of neutropenia associated with ceftaroline or ceftriaxone in patients receiving at least 7 days of therapy for severe infections","volume":"39","author":"Veve","year":"2019","journal-title":"Pharmacotherapy."},{"key":"B28","unstructured":"2025"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"B31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1001\/jama.2010.1205","article-title":"Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction","volume":"304","author":"Psaty","year":"2010","journal-title":"JAMA."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1212\/WNL.0000000000002023","article-title":"Seizures as adverse events of antibiotic drugs: a systematic review","volume":"85","author":"Sutter","year":"2015","journal-title":"Neurology."},{"key":"B33","unstructured":"INVANZ (ertapenem sodium) injection, prescribing information\n          \n          \n            \n              Merck\n              Sharp\n            \n            \n              Dohme\n              LLC\n            \n          \n          DailyMed\n          \n          2026"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1887555\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:12:18Z","timestamp":1784905938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1887555\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":33,"alternative-id":["10.3389\/fmed.2026.1887555"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1887555","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1887555"}}